9995 (9995) Fair Value & Analysis
Healthcare · Market cap HK$47.7B
Fair value as of: Jul 3, 2026
From 17 valuation models · updated today
Share price +4.4% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$54.45 – HK$125.00 · fair‑value band HK$16.50 – HK$83.10 · the HK$80.05 price screens above the HK$22.00 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
9995 (9995) currently trades at HK$80.05, while our model-based Fair Value estimate is HK$22.00 — implying the stock looks roughly 72.5% overvalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, 9995 generated revenue of HK$3.4B at a net margin of 38.2%. Revenue grew 24.8% year over year. It earns a return on equity of 45.3%. Net debt stands at HK$1.0B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
9995 reported revenue of HK$3.2B in FY2025 versus HK$1.4B in FY2021, a compound +22.8%/yr. Reported net income was HK$710M in FY2025, compounding +26.6%/yr from FY2021.
Is 9995 fairly valued? → Check now
Recent news
- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England J
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 9995 (9995) undervalued?
What is the fair value of 9995?
What is the quality score of 9995?
What is the revenue of 9995 (9995)?
What is the net profit margin of 9995?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.